For free samples, call 1-866-318-6977

For free samples, call 1-866-318-6977

IMPORTANT CONTACTS
THAT CAN SUPPORT YOU

See below for a list of resources you may find useful when helping patients start and stay on COSENTYX

Name

Phone/Fax

COSENTYX Connect Personal
Support Program

Monday - Friday, 8:00 AM - 8:30 PM ET

T: 1-844-COSENTYX (1-844-267-3689)

(1-844-267-3689)

F: 1-844-666-1366

COSENTYX Co-pay Program

Monday - Friday, 8:00 AM - 8:30 PM ET

T: 1-844-COSENTYX (1-844-267-3689)

(1-844-267-3689)

Covered Until You're Covered Program

Monday - Friday, 9:00 AM - 6:00 PM ET

T: 1-844-267-3689 or or 1-919-459-5351

1-919-459-5351

F: 1-800-914-0651

Novartis Patient Assistance
Foundation (NPAF)

Monday - Friday, 8:00 AM - 8:00 PM ET

T: 1-800-277-2254

F: 1-855-817-2711

Real Time Medical Information (RTMI)

Monday - Friday, 9:00 AM - 5:00 PM ET

T: 1-844-RTMI-HCP (1-844-786-4427)

(1-844-786-4427)

Novartis Customer Service (NowNova)

Monday - Friday, 8:30 AM - 5:00 PM ET

T: 1-888-NOW-NOVA (1-888-669-6682)

(1-888-669-6682)

INDICATIONS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

WARNINGS AND PRECAUTIONS

Infections

INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.

COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in subjects treated with COSENTYX compared to placebo-treated subjects. In placebo-controlled clinical trials in patients with moderate to severe plaque psoriasis, higher rates of common infections such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%), and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. A similar increase in risk of infection was seen in placebo-controlled trials in patients with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The incidence of some types of infections appeared to be dose-dependent in clinical studies.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection.

Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, the patient should be closely monitored and COSENTYX should be discontinued until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Do not administer COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving COSENTYX should be monitored closely for signs and symptoms of active TB during and after treatment.

Inflammatory Bowel Disease

Caution should be used when prescribing COSENTYX to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred in patients treated with COSENTYX during clinical trials in plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials with COSENTYX. In an exploratory study in 59 patients with active Crohn's disease, there were trends toward greater disease activity and increased adverse events in the secukinumab group as compared to the placebo group. Patients who are treated with COSENTYX should be monitored for signs and symptoms of inflammatory bowel disease.

Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in patients treated with COSENTYX in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable cap of the COSENTYX Sensoready® pen and the COSENTYX prefilled syringe contains natural rubber latex which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Vaccinations

Prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines. Patients treated with COSENTYX should not receive live vaccines.

Non-live vaccinations received during a course of COSENTYX may not elicit an immune response sufficient to prevent disease.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see full Prescribing Information, including Medication Guide.

COSENTYX is broadly available through Specialty Pharmacies via open distribution

Prescriptions may be sent to the Specialty Pharmacy of your choice. Novartis has contracted with the Specialty Pharmacies listed below.

Name

Phone

Fax

AcariaHealth

Dermatology

T: 1-800-511-5144

F: 1-877-541-1503

Rheumatology

T: 1-866-892-1580

F: 1-866-892-2362

1-800-511-5144

1-866-892-1580

1-877-541-1503

1-866-892-2362

Albertsons Specialty Care

T: 1-877-770-4633

F: 1-877-771-4633

1-877-770-4633

1-877-771-4633

AltScripts Specialty Care

T: 1-414-385-9500

F: 1-414-385-7200

1-414-385-9500

1-414-385-7200

BioPlus Specialty Pharmacy

Florida

T: 1-888-292-0744

F: 1-800-269-5493

North Carolina

T: 1-866-514-8082

F: 1-919-650-2604

1-888-292-0744

1-866-514-8082

1-800-269-5493

1-919-650-2604

Duncan Prescription Center

T: 1-270-247-3725

F: 1-270-247-6033

1-270-247-3725

1-270-247-6033

FOSRX/FAST

T: 1-833-367-3278

F: 1-844-504-3278

1-833-367-3278

1-844-504-3278

Giannotto's Specialty Pharmacy

T: 1-973-482-8220

F: 1-844-587-9625

1-973-482-8220

1-844-587-9625

Good Health Pharmacy, Inc.

T: 1-718-296-7000

F: 1-718-296-7001

1-718-296-7000

1-718-296-7001

Kroger Specialty Pharmacy

T: 1-888-355-4191

F: 1-888-355-4192

1-888-355-4191

1-888-355-4192

Noble Health Services

New York

T: 1-888-843-2040

F: 1-888-842-3977

Mississippi

T: 1-866-420-4041

F: 1-601-420-4040

1-888-843-2040

1-866-420-4041

1-888-842-3977

1-601-420-4040

Owl Specialty Pharmacy

T: 1-626-209-8169

F: 1-626-209-8171 or 1-855-817-9523

1-626-209-8169

1-626-209-8171 or

1-855-817-9523

Parkway Pharmacy

T: 1-866-355-7797

F: 1-888-551-6289

1-866-355-7797

1-888-551-6289

Patient First Services Pharmacy

New York

T: 1-844-527-9486

F: 1-866-286-4126

New Jersey

T: 1-844-527-9486

F: 1-866-285-7628

1-844-527-9486

1-844-527-9486

1-866-286-4126

1-866-285-7628

Publix Specialty Pharmacy

T: 1-855-797-8254

F: 1-863-413-5723

1-855-797-8254

1-863-413-5723

Senderra Rx

T: 1-855-460-7928

F: 1-888-777-5645

1-855-460-7928

1-888-777-5645

Special Care Pharmacy Services

T: 1-787-781-4585

F: 1-787-783-2951

1-787-781-4585

1-787-783-2951

Sterling Specialty Pharmacy

T: 1-888-618-4126

F: 1-866-588-0371

1-888-618-4126

1-866-588-0371

Thrifty White Drug Stores, Inc

T: 1-855-611-3399

F: 1-855-423-8300

1-855-611-3399

1-855-423-8300

Novartis does not recommend the use of any particular Specialty Pharmacy.
The list of Enhanced Specialty Pharmacy Providers is updated regularly.Download pdf